Back to Search Start Over

Galectin-3, a rising star in modulating microglia activation under conditions of neurodegeneration

Authors :
Juan García-Revilla
Antonio Boza-Serrano
Ana M. Espinosa-Oliva
Manuel Sarmiento Soto
Tomas Deierborg
Rocío Ruiz
Rocío M. de Pablos
Miguel Angel Burguillos
Jose L. Venero
Universidad de Sevilla. Departamento de Bioquímica y Biología Molecular
Ministerio de Ciencia, Innovación y Universidades (España)
European Commission
Agencia Estatal de Investigación (España)
Junta de Andalucía
Universidad de Sevilla
Lund University
Swedish Alzheimer Foundation
Swedish Brain Foundation
Crafoord Foundation
Dementia Association (Sweden)
Greta and Johan Kocks Foundation
Olle Engkvist Foundation
Swedish Research Council
Anna och Edwin Bergers Stiftelse
Swedish Parkinson Foundation
Source :
Cell Death & Disease. 13
Publication Year :
2022
Publisher :
Springer Science and Business Media LLC, 2022.

Abstract

The advent of high-throughput single-cell transcriptomic analysis of microglia has revealed different phenotypes that are inherently associated with disease conditions. A common feature of some of these activated phenotypes is the upregulation of galectin-3. Representative examples of these phenotypes include disease-associated microglia (DAM) and white-associated microglia (WAM), whose role(s) in neuroprotection/neurotoxicity is a matter of high interest in the microglia community. In this review, we summarise the main findings that demonstrate the ability of galectin-3 to interact with key pattern recognition receptors, including, among others, TLR4 and TREM2 and the importance of galectin-3 in the regulation of microglia activation. Finally, we discuss increasing evidence supporting the involvement of this lectin in the main neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, and stroke.<br />We thank the Spanish Ministerio de Ciencia, Innovación y Universidades/FEDER/UE RTI2018-098645-B-100, PID2019-107948RA-I00 and RYC-2017-21804; the Agencia Española de Investigación PID2021-124096OB-I00 and PID2021-126090OA-I00; the Spanish Junta de Andalucia /FEDER/EU P18-RT-1372 and the Spanish FEDER I + D + i-USE US-1264806, US-1264152 and US-1265062 from University of Seville. This work has also been supported by the Strategic Research Area MultiPark (Multidisciplinary Research focused on neurodegenerative diseases) at Lund University, the Swedish Alzheimer foundation, the Swedish Brain Foundation, the Crafoord Foundation, the Swedish Dementia Association, the G&J Kock Foundation, the Olle Engkvist Foundation, the Swedish Research Council (Project 2019-06333), the Royal Physiographic Society (42222 and 40594), the A.E. Berger Foundation, the Swedish Parkinson Foundation and the Medical Faculty at Lund University. Open access funding provided by Lund University.

Details

ISSN :
20414889
Volume :
13
Database :
OpenAIRE
Journal :
Cell Death & Disease
Accession number :
edsair.doi.dedup.....66c3ee5af6d92dadc8d032e3fb3d9740
Full Text :
https://doi.org/10.1038/s41419-022-05058-3